{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T07:16:22Z","timestamp":1783581382626,"version":"3.55.0"},"reference-count":31,"publisher":"Georg Thieme Verlag KG","issue":"04","funder":[{"name":"Pfizer Ltd. and Bristol-Myers Squibb"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:p>\n            Background\u2003Cancer-associated venous thromboembolism (Ca-VTE) treatment with anticoagulation is associated with bleeding complications and there are limited data on risk factors. Current models do not provide accurate bleeding risk prediction.<\/jats:p><jats:p>\n            Methods\u2003UK Clinical Practice Research Datalink data (2008\u20132020) were used to generate a cohort of patients with anticoagulant initiation for first Ca-VTE. Patients were observed up to 180 days for significant bleeding including major bleeding and clinically relevant nonmajor bleeding requiring hospitalization (CRNMB-H). A scoring scheme was developed from sub-distribution hazard ratios, and its discrimination (expressed by the C-statistic) estimated from cross-validation.<\/jats:p><jats:p>\n            Results\u2003A total of 15,749 patients with Ca-VTE and anticoagulant treatment were included. In total, 537 significant bleeding events, 161 major bleeds, and 376 CRNMB-H were identified after adjudicated review in 4,914 person-years of observation. Incidence rates of 3.3 and 7.7 per 100 person-years were noted for major bleeding and CRNMB-H. Independent predictors of significant bleeding included cancer of the bladder, central nervous system, cervix, kidney, melanoma, prostate and upper gastrointestinal tract, metastases, minor surgery, minor trauma, and history of major bleeding or CRNMB (before or after the Ca-VTE diagnosis). Patients recognized as low, medium, and high risk (30.4, 56.8, and 1.7% of the population, respectively) had a 6-month significant bleeding incidence rate of 5.1, 19.0, and 56.5 per 100 person-years, respectively. Overall C-statistic for significant bleeding was 0.70 (95% confidence interval: 0.65\u20130.75), and 0.76 (0.68\u20130.84) and 0.67 (0.61\u20130.73) for major bleeding and for CRNMB-H, respectively.<\/jats:p><jats:p>\n            Conclusion\u2003This risk score may identify patients at risk of significant bleeding, while also helping to determine treatment duration.<\/jats:p>","DOI":"10.1055\/a-2145-7238","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T23:02:51Z","timestamp":1690930971000},"page":"324-336","source":"Crossref","is-referenced-by-count":18,"title":["A Novel Risk Prediction Score for Clinically Significant Bleeding in Patients Anticoagulated for Venous Thromboembolism with Active Cancer"],"prefix":"10.1055","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9398-4621","authenticated-orcid":false,"given":"Alexander T.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Haematology, Guy's and St Thomas' Hospitals, NHS Foundation Trust, King's College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7944-7347","authenticated-orcid":false,"given":"Christopher","family":"Wallenhorst","sequence":"additional","affiliation":[{"name":"Institute for Epidemiology, Statistics and Informatics GmbH, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satarupa","family":"Choudhuri","sequence":"additional","affiliation":[{"name":"Northern Care Alliance NHS Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Nassar","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb Pharmaceuticals Ltd., Uxbridge, Middlesex, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5298-0504","authenticated-orcid":false,"given":"Kevin G.","family":"Pollock","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb Pharmaceuticals Ltd., Uxbridge, Middlesex, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6498-6428","authenticated-orcid":false,"given":"Carlos","family":"Martinez","sequence":"additional","affiliation":[{"name":"Institute for Epidemiology, Statistics and Informatics GmbH, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2023,9,11]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1160\/TH15-08-0686","article-title":"Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study","volume":"117","author":"A T Cohen","year":"2017","journal-title":"Thromb Haemost"},{"issue":"10","key":"ref2","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"P Prandoni","year":"2002","journal-title":"Blood"},{"issue":"02","key":"ref3","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s11239-020-02180-x","article-title":"Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE","volume":"50","author":"J I Weitz","year":"2020","journal-title":"J Thromb Thrombolysis"},{"issue":"02","key":"ref4","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"C Kearon","year":"2016","journal-title":"Chest"},{"issue":"09","key":"ref5","doi-asserted-by":"crossref","first-page":"578","DOI":"10.7326\/0003-4819-152-9-201005040-00008","article-title":"Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism","volume":"152","author":"M Carrier","year":"2010","journal-title":"Ann Intern Med"},{"issue":"11","key":"ref6","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1111\/jth.13139","article-title":"Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"C Chai-Adisaksopha","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref7","first-page":"834","article-title":"Dynamics of case-fatalilty rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism","volume":"110","author":"R Lecumberri","year":"2013","journal-title":"Thromb Haemost"},{"issue":"08","key":"ref8","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.3390\/cancers14081937","article-title":"In search of the appropriate anticoagulant-associated bleeding risk assessment model for cancer-associated thrombosis patients","volume":"14","author":"G Po\u00e9nou","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"05","key":"ref9","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1055\/s-0041-1735251","article-title":"Estimating bleeding risk in patients with cancer-associated thrombosis: evaluation of existing risk scores and development of a new risk score","volume":"122","author":"M A de Winter","year":"2022","journal-title":"Thromb Haemost"},{"issue":"08","key":"ref10","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1111\/jth.15776","article-title":"Management of bleeding risk in patients who receive anticoagulant therapy for venous thromboembolism: communication from the ISTH SSC Subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease","volume":"20","author":"P L den Exter","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref11","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1001\/archinte.159.5.457","article-title":"Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism","volume":"159","author":"P M Kuijer","year":"1999","journal-title":"Arch Intern Med"},{"issue":"01","key":"ref12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1160\/TH08-03-0193","article-title":"Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism","volume":"100","author":"N Ru\u00edz-Gim\u00e9nez","year":"2008","journal-title":"Thromb Haemost"},{"issue":"05","key":"ref13","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"R Pisters","year":"2010","journal-title":"Chest"},{"issue":"04","key":"ref14","doi-asserted-by":"crossref","first-page":"e0122520","DOI":"10.1371\/journal.pone.0122520","article-title":"The HAS-BLED score identifies patients with acute venous thromboembolism at high risk of major bleeding complications during the first six months of anticoagulant treatment","volume":"10","author":"J Kooiman","year":"2015","journal-title":"PLoS One"},{"issue":"05","key":"ref15","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1183\/13993003.00280-2016","article-title":"Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment","volume":"48","author":"F A Klok","year":"2016","journal-title":"Eur Respir J"},{"issue":"02","key":"ref16","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1160\/th15-06-0474","article-title":"Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists","volume":"115","author":"M Di Nisio","year":"2016","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref17","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1160\/TH16-11-0830","article-title":"Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonists","volume":"117","author":"M Di Nisio","year":"2017","journal-title":"Thromb Haemost"},{"issue":"03","key":"ref18","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/bjh.16383","article-title":"Prediction of significant bleeding during vitamin K antagonist treatment for venous thromboembolism in outpatients","volume":"189","author":"C Martinez","year":"2020","journal-title":"Br J Haematol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.thromres.2020.12.031","article-title":"Prediction models for recurrence and bleeding in patients with venous thromboembolism: a systematic review and critical appraisal","volume":"199","author":"M A de Winter","year":"2021","journal-title":"Thromb Res"},{"issue":"09","key":"ref20","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1055\/s-0039-1692425","article-title":"Risk factors for major bleeding during prolonged anticoagulation therapy in patients with venous thromboembolism: from the COMMAND VTE registry","volume":"119","author":"K Kim","year":"2019","journal-title":"Thromb Haemost"},{"issue":"S 01","key":"ref21","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1016\/S0049-3848(16)30106-2","article-title":"Predictors of recurrent venous thromboembolism and bleeding on anticoagulation","volume":"140","author":"L A Menapace","year":"2016","journal-title":"Thromb Res"},{"issue":"03","key":"ref22","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1160\/TH08-02-0125","article-title":"Predicting recurrences or major bleeding in cancer patients with venous thromboembolism","volume":"100","author":"J Trujillo-Santos","year":"2008","journal-title":"Thromb Haemost"},{"issue":"11","key":"ref23","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1253\/circj.CJ-20-0223","article-title":"Risk factors for major bleeding during anticoagulation therapy in cancer-associated venous thromboembolism. From the COMMAND VTE registry","volume":"84","author":"Y Nishimoto","year":"2020","journal-title":"Circ J"},{"issue":"03","key":"ref24","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.amjmed.2016.10.017","article-title":"The clinical course of venous thromboembolism may differ according to cancer site","volume":"130","author":"I Mahe","year":"2017","journal-title":"Am J Med"},{"issue":"09","key":"ref25","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.3324\/haematol.13055","article-title":"Recurrent thromboembolism and major bleeding during oral anticoagulant therapy in patients with solid cancer: findings from the RIETE registry","volume":"93","author":"P Prandoni","year":"2008","journal-title":"Haematologica"},{"issue":"02","key":"ref26","first-page":"255","article-title":"Epidemiology of first and recurrent venous thromboembolism: a population-based cohort study in patients without active cancer","volume":"112","author":"C Martinez","year":"2014","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref27","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"S Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"07","key":"ref28","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/sj.bjc.6602102","article-title":"A note on competing risks in survival data analysis","volume":"91","author":"J M Satagopan","year":"2004","journal-title":"Br J Cancer"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1214\/09-SS054","article-title":"A survey of cross-validation procedures for model selection","volume":"4","author":"S Arlot","year":"2010","journal-title":"Stat Surv"},{"issue":"04","key":"ref30","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"G H Lyman","year":"2021","journal-title":"Blood Adv"},{"issue":"06","key":"ref31","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","article-title":"Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report","volume":"160","author":"S M Stevens","year":"2021","journal-title":"Chest"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2145-7238.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T11:56:57Z","timestamp":1730807817000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2145-7238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":31,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2024,3,26]]},"published-print":{"date-parts":[[2024,4]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2145-7238","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8,1]]},"published":{"date-parts":[[2023,8,1]]}}}